ClinicalTrials.gg
CompletedNCT01895231Updated Mar 15, 2018

A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors

A Phase 3 interventional study of Iron isomaltoside 1000 (Monofer®) and Placebo in Iron-deficiency, sponsored by Pharmacosmos A/S. Completed at 1 site in Denmark. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-15.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Enrollment
19th of 32
107 · median 121
Started
2013
the only one that year
Phase 3
18 of 32
4 open now
Registered
4th of 32
by date
Lead sponsor
13 of 32
Pharmacosmos A/S

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 19th largest by enrollment, is the only one that started in 2013, is one of 18 in phase 3, and was the 4th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the effect of IV iron isomaltoside 1000 compared with placebo on Hb in first-time female donors with p-ferritin below 30 µg/L

Read the detailed description

At present, clinical efficacy and safety data is available for iron isomaltoside 1000 administered to patients with IDA requiring iron therapy. However, there is a need for clinical efficacy and safety data within iron deficiency without anaemia which is e.g. observed in blood donors. Thus, this study is planned to compare the efficacy and safety of parenteral iron isomaltoside 1000 with placebo in female blood donors with a p-ferritin below 30 µg/L.

03

Conditions studied

  • Iron-deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women aged ≥ 18 years
  2. First-time donor
  3. P-ferritin \< 30 µg/L
  4. Willingness to participate and signed the form

Exclusion criteria

Exclusion Criteria:

  1. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
  2. Known to any in the drug products
  3. History of drug related allergies
  4. History of severe asthma
  5. Decompensated liver cirrhosis and hepatitis (defined as ALAT > 3 times )
  6. Active acute or chronic infections (assessed by clinical judgement supplied with White Blood Cells (WBC) and C-Reactive Protein (CRP))
  7. Rheumatoid arthritis with symptoms or signs of active inflammation
  8. Subjects who are pregnant or nursing. In order to avoid pregnancy, women have to be (at least 12 months since last menstruation), surgically sterile, or use one of the following during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: intrauterine devices and hormonal contraceptives (contraceptive pills, implants, transdermal patches, vaginal devices, or hormonal injections with prolonged release)
  9. Participation in any other clinical study where the study drug has not passed 5 half-lives prior to the screening
  10. Untreated vitamin B12 or folate deficiency
  11. Treated with other IV or oral iron products within 4 weeks prior to the screening
  12. Treated with Erythropoietin (EPO) within 4 weeks prior to the screening
  13. Any other medical condition that, in the opinion of the Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Iron isomaltoside 1000

    Monofer® 1000 mg IV infusion over 15 minutes

    Drug: Iron isomaltoside 1000 (Monofer®)

  • Placebo comparator
    Placebo

    0.9 % saline Infusion over 15 min

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Hb concentration

    The primary endpoint is to measure and compare the change in Hb concentration from baseline to right before the third blood donation in the two study arms

    Time frame: From baseline and until t= 6 months

Secondary outcomes

  1. Change in Hb concentration

    Change in Hb concentrations from baseline to right before second donation

    Time frame: From baseline and until t=3 months

  2. Ability to complete 3 blood donations

    Number of subjects who cannot complete three donations due to low Hb

    Time frame: From baseline and until t=6 months

  3. Change in p-iron

    Time frame: From baseline and until week 12

  4. Change in fatigue symptoms

    Time frame: From baseline and until week 12

  5. Exercise tolerance

    Change in exercise tolerance from baseline to 3 weeks after baseline measured by a two-step test on bike

    Time frame: From baseline to week 3

  6. Number of adverse drug reactions

    Time frame: From screening and until t= 6 months

  7. Change in p-ferritin

    Time frame: From baseline and until week 12

  8. Change in Transferrin Saturation (TSAT)

    Time frame: From baseline until week 12

  9. Change in reticulocyte count

    Time frame: From Baseline to week 12

  10. Change in haematology parameters

    Time frame: From baseline and until t= 6 months

  11. Change in RLS symptoms

    Time frame: From baseline and until t= 6 months

07

Study locations

1 site
  • Copenhagen, Denmark
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jul 10, 2013
Start
Jun 2013
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Last update
Mar 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01895231
Lead sponsor
Pharmacosmos A/S
Collaborators
Max Neeman
Responsible party
Sponsor
First posted
Jul 10, 2013
Start date
Jun 2013
Primary completion
Dec 2016
Completion
Dec 2016
Last update
Mar 15, 2018

Study contacts

Nørgaard
principal investigator · RH Blodbanken

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion